Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2018
At a glance
- Drugs Posaconazole (Primary) ; Posaconazole (Primary)
- Indications Mycoses
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 09 Apr 2018 Planned End Date changed from 15 Sep 2018 to 23 Nov 2018.
- 09 Apr 2018 Planned primary completion date changed from 15 Sep 2018 to 23 Nov 2018.
- 25 Dec 2017 Status changed from not yet recruiting to recruiting.